FDA Adverse Event Injury Summary report: N

VERCISE? CARTESIA?

MDR report key: 22413637 · Received July 7, 2025

Report

Report Number
3006630150-2025-05201
Event Type
Injury
Date Received
July 7, 2025
Date of Event
August 10, 2024
Report Date
September 9, 2025
Manufacturer
BOSTON SCIENTIFIC NEUROMODULATION CORPORATION
Product Code
NHL
UDI-DI
08714729905288
PMA / PMN Number
P150031
Adverse Event
Yes
Report Source
Manufacturer report
Reporter Location
TU
Reporter Occupation
PHYSICIAN
Health Professional
Yes

Narratives

Additional Manufacturer Narrative · 0

CORRECTION TO INITIAL MDR BSC AWARE DATE (G3): 24JUN2025. ADDITIONAL SUSPECT MEDICAL DEVICE COMPONENT INVOLVED IN THE EVENT: PRODUCT FAMILY: DBS-LINEAR LEADS. UPN: M365DB2202450. MODEL: DB-2202-45. SERIAL: (B)(6). BATCH: 7120341.

Additional Manufacturer Narrative · 0

ADDITIONAL SUSPECT MEDICAL DEVICE COMPONENT INVOLVED IN THE EVENT: PRODUCT FAMILY: DBS-LINEAR LEADS, UPN: M365DB2202450, MODEL: DB-2202-45, SERIAL: (B)(6), BATCH: 7120341, UDI: (B)(4).

Additional Manufacturer Narrative · 0

BLOCK B3: APPROXIMATED BASED ON THE DATE THE MANUFACTURER BECAME AWARE OF THE EVENT. GOOD FAITH EFFORT ATTEMPTS WERE MADE TO TRY AND RETRIEVE ADDITIONAL DETAILS REGARDING THE REPORTED EVENT, BUT FURTHER INFORMATION WAS UNABLE TO BE OBTAINED. ADDITIONAL SUSPECT MEDICAL DEVICE COMPONENT INVOLVED IN THE EVENT: PRODUCT FAMILY: DBS-LINEAR LEADS, UPN: M365DB2202450, MODEL: DB-2202-45, SERIAL: (B)(6), BATCH: 7120341.

Additional Manufacturer Narrative · 0

CORRECTION TO SUPPLEMENTAL 1 MDR BSC AWARE DATE (G3): 04JUL2025. ADDITIONAL SUSPECT MEDICAL DEVICE COMPONENT INVOLVED IN THE EVENT: PRODUCT FAMILY: DBS-LINEAR LEADS, UPN: M365DB2202450, MODEL: DB-2202-45, SERIAL: (B)(6), BATCH: 7120341, UDI: (B)(4).

Description of Event or Problem · 0

IT WAS REPORTED THAT FOLLOWING A DEEP BRAIN STIMULATION (DBS) IMPLANT PROCEDURE, THE PATIENT DEVELOPED LOCALIZED EDEMA AT THE DISTAL END OF THE LEAD, RESULTING IN INFLAMMATION AND SWELLING. ADDITIONAL UNSPECIFIED SIDE EFFECTS WERE ALSO REPORTED. ADMINISTRATION OF CORTICOSTEROIDS LED TO SIGNIFICANT SYMPTOM RESOLUTION. COMPUTED TOMOGRAPHY (CT) SCANS WERE PERFORMED TO ASSESS THE CONDITION. ADDITIONAL INFORMATION WAS RECEIVED THAT THE PATIENT EXPERIENCED A POSTOPERATIVE HEMORRHAGE AND BILATERAL EDEMA WITHIN TWO WEEKS OF SURGERY. THESE COMPLICATIONS WERE EFFECTIVELY MANAGED AND RESOLVED THROUGH THE ADMINISTRATION OF CORTICOSTEROIDS.

Description of Event or Problem · 0

IT WAS REPORTED THAT FOLLOWING A DEEP BRAIN STIMULATION (DBS) IMPLANT PROCEDURE, THE PATIENT DEVELOPED LOCALIZED EDEMA AT THE DISTAL END OF THE LEAD, RESULTING IN INFLAMMATION AND SWELLING. ADDITIONAL UNSPECIFIED SIDE EFFECTS WERE ALSO REPORTED. ADMINISTRATION OF CORTICOSTEROIDS LED TO SIGNIFICANT SYMPTOM RESOLUTION. COMPUTED TOMOGRAPHY (CT) SCANS WERE PERFORMED TO ASSESS THE CONDITION. THE PATIENTS DBS SYSTEM WAS PROGRAMMED, AND THE PATIENT WAS DERIVING A BENEFIT FROM IT. ADDITIONAL INFORMATION WAS RECEIVED THAT THE PATIENT EXPERIENCED A POSTOPERATIVE HEMORRHAGE AND BILATERAL EDEMA WITHIN TWO WEEKS OF SURGERY. THESE COMPLICATIONS WERE EFFECTIVELY MANAGED AND RESOLVED THROUGH THE ADMINISTRATION OF CORTICOSTEROIDS. ADDITIONAL INFORMATION WAS RECEIVED THAT THE PATIENT ALSO EXPERIENCED URINARY INCONTINENCE. THE BILATERAL-SIDED PERI-LEAD EDEMA PERSISTED FOR A DURATION OF APPROXIMATELY ONE WEEK TO ONE MONTH PRIOR TO RESOLUTION. INITIAL SYMPTOM IMPROVEMENT WAS OBSERVED WITHIN 5 TO 7 DAYS TO 1 MONTH DAYS FOLLOWING THE ONSET OF TREATMENT.

Description of Event or Problem · 0

IT WAS REPORTED THAT FOLLOWING A DEEP BRAIN STIMULATION (DBS) IMPLANT PROCEDURE, THE PATIENT DEVELOPED LOCALIZED EDEMA AT THE DISTAL END OF THE LEAD, RESULTING IN INFLAMMATION AND SWELLING. ADDITIONAL UNSPECIFIED SIDE EFFECTS WERE ALSO REPORTED. ADMINISTRATION OF CORTICOSTEROIDS LED TO SIGNIFICANT SYMPTOM RESOLUTION. COMPUTED TOMOGRAPHY (CT) SCANS WERE PERFORMED TO ASSESS THE CONDITION.

Description of Event or Problem · 0

IT WAS REPORTED THAT FOLLOWING A DEEP BRAIN STIMULATION (DBS) IMPLANT PROCEDURE, THE PATIENT DEVELOPED LOCALIZED EDEMA AT THE DISTAL END OF THE LEAD, RESULTING IN INFLAMMATION AND SWELLING. ADDITIONAL UNSPECIFIED SIDE EFFECTS WERE ALSO REPORTED. ADMINISTRATION OF CORTICOSTEROIDS LED TO SIGNIFICANT SYMPTOM RESOLUTION. COMPUTED TOMOGRAPHY (CT) SCANS WERE PERFORMED TO ASSESS THE CONDITION. ADDITIONAL INFORMATION WAS RECEIVED THAT THE PATIENT EXPERIENCED A POSTOPERATIVE HEMORRHAGE AND BILATERAL EDEMA WITHIN TWO WEEKS OF SURGERY. THESE COMPLICATIONS WERE EFFECTIVELY MANAGED AND RESOLVED THROUGH THE ADMINISTRATION OF CORTICOSTEROIDS.

Devices

Seq Brand Generic Product Code Manufacturer Model Lot UDI-DI
2757761 VERCISE? CARTESIA? STIMULATOR, ELECTRICAL, IMPLANTED, FOR PARKINSONIAN TREMOR NHL BOSTON SCIENTIFIC NEUROMODULATION CORPORATION DB-2202-45 7120265 08714729905288

Patients

Seq Age Sex Outcome Treatment
1 NA Unknown Required Intervention